getmoreshares
1 year ago
. Pursuant to the Inducement Letter, upon the exercise of any Existing Warrants, the reduced exercise price for such Existing Warrants during the Reduced Price Exercise Period shall be $0.1395 per share (the βReduced Exercise Priceβ). The issuance, or resale, of shares of Common Stock underlying the Existing Warrants have been registered pursuant to effective registration statements (File Nos. 333-273256, 333-235945 and 333-272254). We anticipate receiving aggregate gross proceeds of up to approximately $3.9 million from the exercise of the Existing Warrants before deducting financial advisory fees and other expenses payable by us.
Ecomike
1 year ago
Read the latest SEC filings, 2.5 Mil dollar cash burn every 4 weeks, and .34 stock price head for OTC Markets, and not sure they can even do another R/S or if it would even help.
Give me some facts if you have any. I bought the bottom dip 2 times and now that is down 95 to 99% in just 12 months.
Market cap of 7 Mil is not going to cover $2,500,000/month cash burn list in the latest filings
goupupup
2 years ago
ATHX is going to remain in business a lot longer now that the underwriting of the 13,000,000 shares has been completed last week. The underwriting was effective and it signals the deal was done. Fees was paid to underwriters and felt the need for capital was the primary concern with money flow into this company. Let's not forget regarding the short mafia might deserting their course rather than see additional funding extend the life of the company, even if the company fails, it's still a positive delay. The negative chatter about restrictions of public offerings to 30 / 33% of the outstanding, is negative, as it hand ties the fund raising efforts of the current management before even knowing the current pressing situation. There probably a lot of ?????????????? the volatility of the stock, the above items could easily influence the price, especially because of the light volume. The good news that the shares price have maintained a okay performance ... GOOD LUCK LONGS
goupupup
2 years ago
Something else is brewing regarding Japan's Kyocera pulling out of Australia's Regeneus deal for stem cell therapy Progenza for osteoarthritis which ATHX seems to be in play ...
News of the deal falling apart is a particular blow to Regeneus, because it saw the deal as a validation of its technology, and it specifically chose the Japan market as its entry point because it believed it would quickly gain approval and be able to commercialize the product in other territories. Under the terms of the deal, Regeneus, of Sydney, was to receive $19 million in up-front and milestone payments, consisting of $9 million up front and $10 million in regulatory and development milestones. Regeneus would have also received double-digit royalties on sales and retained rights to negotiate licenses with other partners for additional indications inside and outside of Japan.
Check out Athersys' leadership page on the company's website which has been updated. The timing regarding of the announcement is positive. Dan has been AVOIDING any mention of a partnership until it is a done deal, something that could happen VERY soon. Get your ????? in order which they are inviting people to submit ??????????? .... GOOD LUCK LONGS